Cathay Industrial Biotech

Cathay Industrial Biotech, founded in 1997, is a pioneer in industrial biotechnology, specializing in the commercial-scale production of bio-based materials. The company focuses on independent R&D to develop economically viable solutions, including long-chain dibasic acids (LCDA), bio-based butanol, 1,5-pentanediamine (DN5), and bio-based polyamide. By leveraging proprietary synthetic biology, the firm produces specialty chemical materials that offer superior performance and cost-efficiency compared to traditional chemical synthesis methods. Meet Cathay Industrial Biotech's team to understand the expertise driving these innovations.

The company operates with 1,000-5,000 employees across its R&D and manufacturing infrastructure. Its primary R&D center is situated in the Shanghai Zhangjiang Hi-Tech Park, a hub for high-tech development. Production capabilities are anchored by two major sites: the Shandong Jinxiang facility, commercialized in 2002 with a 40,000-ton annual capacity, and the Xinjiang Wusu site. The latter represents a significant capital investment exceeding $400.0M, designed to scale production to 50,000 tons of DN5, 100,000 tons of bio-based polyamide, and 30,000 tons of LCDA annually.

Cathay Industrial Biotech maintains a strong market position within the chemicals and manufacturing sectors. With a reported revenue of $86.5M, the company continues to expand its industrial footprint through strategic investments and advanced biotechnology implementation. Explore financial highlights to review the firm's fiscal performance and funding history, including its $135.0M private equity round in 2015. The company remains committed to advancing sustainable chemical production through its proprietary R&D pipeline and large-scale manufacturing operations.